Adaptive Biotechnologies Corporation Announces Results of 2026 Annual Meeting of Shareholders
SEATTLE, WA – June 9, 2026 – Adaptive Biotechnologies Corporation (“Adaptive” or the “Company”) has disclosed the results of its 2026 Annual Meeting of Shareholders, held on June 5, 2026. Shareholders were asked to vote on three key proposals, each of which may be of significant interest to investors and could impact future company performance and share value.
Key Highlights from the Annual Meeting
- Election of Directors: Two Class I directors—Robert Hershberg, PhD, MD and Katey Owen, PhD—were standing for election to the Board of Directors.
- Advisory Vote on Executive Compensation: Shareholders considered an advisory vote regarding compensation for the Company’s named executive officers for 2025.
- Ratification of Independent Auditor: Ernst & Young LLP was presented for ratification as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Detailed Voting Results
Proposal 1: Election of Directors
| Outcome | Votes For | Percent For | Votes Against | Percent Against | Withhold/Abstain | Percent Withhold/Abstain | Broker Non-Vote |
|---|---|---|---|---|---|---|---|
| Director Election (Aggregate) | 93,188,652 | 71.81% | 36,556,043 | 28.19% | 158,599 | 0.12% | 0 |
Investor Insight: Both directors received strong support, with more than 71% voting “For,” indicating shareholder confidence in current leadership and strategic direction.
Proposal 2: Advisory Vote on Executive Compensation (Say-on-Pay)
| Votes For | Percent For | Votes Against | Percent Against | Withhold/Abstain | Percent Withhold/Abstain | Broker Non-Vote |
|---|---|---|---|---|---|---|
| 125,287,618 | 96.55% | 4,316,144 | 3.33% | 158,599 | 0.12% | 0 |
Investor Insight: The overwhelming approval (over 96%) of executive compensation is a strong signal that shareholders are generally satisfied with management performance and its alignment with shareholder interests.
Proposal 3: Ratification of Independent Auditor (Ernst & Young LLP)
| Votes For | Percent For | Votes Against | Percent Against | Broker Non-Vote |
|---|---|---|---|---|
| 126,803,695 | 97.72% | 484,798 | 0.34% | 0 |
Investor Insight: The near-unanimous ratification of Ernst & Young LLP as the Company’s independent auditor for 2026 reflects trust in the Company’s financial reporting and governance practices.
Other Regulatory Matters
- The Form 8-K confirms that the Company does not intend to simultaneously satisfy any obligations related to written communications, solicitation materials, or pre-commencement tender offer communications under SEC rules. The Company is not considered an emerging growth company.
- Security Information: Adaptive Biotechnologies common stock (par value \$0.0001 per share) is listed and traded on The Nasdaq Stock Market LLC under the symbol “ADPT”.
What Shareholders Need to Know
- Strong Shareholder Support: All proposals received high levels of approval, with directors and management compensation both supported by more than 70% and 96% of votes cast, respectively. This signals stability in governance and alignment with shareholder expectations.
- No Indication of Strategic Changes: The report contains no announcements of M&A, buybacks, dividends, or changes in business strategy.
- Governance Continuity: The re-election of current directors and ratification of the auditor suggest continuity in strategic oversight and financial reporting.
Potential Share Price Impact
While the results reflect strong shareholder support and confidence in management and board leadership, there are no new strategic initiatives, material events, or surprise actions disclosed that would typically be considered price-sensitive or likely to move the share price in the short term. The outcomes are consistent with standard governance practices at public companies.
Disclaimer: This article is for informational purposes only and is not intended as investment advice. Investors should review official filings and consult their financial advisors before making investment decisions. The author and publisher assume no responsibility for decisions made based on this summary.
